ARPIs, SPARC and Organised Prostate Testing | With Anders Bjartell

It is the eve of the USANZ ASM here in Melbourne (which Renu is Convening!), and some of the 27 International guests are already into town. So we grabbed Anders Bjartell (Lund University/University Hospital Malmo, SWE), for a sit down chat in studio. Anders has been a huge name in prostate cancer research in Europe for the past couple of decades, including as a senior investigator on TITAN. so we decided to pick his brain on three topical areas in prostate cancer:

1. ADT/ARPI doublets in mHSPC - can we adopt an intermittent approach before the trials read out? What about docetaxel triplet therapy?

2. The SPARC consensus on PSMA PET/CT reporting - Anders led this initiative which recently publihsed in Eur Urol. What is this and why does it matter?

3. Organised Prostate Testing - what is the difference between screening and organised prostate testing?

With usual hosts Renu Eapen and Declan Murphy

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson.

Links:

SPARC consensus paper in European Urology

Also available as an audio podcast - just search GU Cast wherever you get your podcasts, or play directly below